0.2%溴莫尼定、0.15%乌诺前列酮分别加入0.5%马来酸噻吗洛尔眼液2次/d治疗原发性开角型青光眼或高眼压症
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-an-gle glaucoma or ocular hypertension作者机构：Pharmaceutical Research Network LLC 1639 Tatum Street Charleston SC 29412- 2464 United States
出 版 物：《世界核心医学期刊文摘（眼科学分册）》 (Digest of the World Core Medical Journals:Ophthalmology)
年 卷 期：2005年第1卷第6期
页 面：34-35页
学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学]
主 题：高眼压症 马来酸噻吗洛尔 乌诺 眼压值 莫尼 眼内压 感觉点 上均
摘 要：Purpose. To compare the efficacy and safety of brimonidine 0.2% vs unoprostone 0.15% , both added to timolol maleate 0.5% each given twice daily. Methods. In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6- week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period. Results. In all,33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3± 2.4 and the diurnal curve IOP was 22.0± 1.3mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6± 3.3 and the diurnal curve IOPwas 19.8± 2.1mmHg,while the timolol and unoprostone treatment showed a trough IOP of 20.9± 3.8 and a diurnal curve IOP of 19.3± 2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve,or in the reduction from baseline (P 0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (P=0.02) and burning upon instillation (P 0.0001) with unoprostone by survey. Conclusion. Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.
维普期刊数据库
同方期刊数据库